Journals / art / 2015 / Cilt: 30 - Sayı: 1

Evaluation of various factors leading to osteolytic and antiosteolytic effects in patients with rheumatoid arthritis

Journal
art
Pages
45–50
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Widespread use of these parameters may be beneficial for the early diagnosis and effective treatment of RA and similar diseases resulting in bone deformities in the future.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: This study aims to evaluate the biomarkers of bone formation and resorption to determine the mechanism of bone deformities in patients with rheumatoid arthritis (RA).
📊
Key Findings & Data:Patients and methods: Thirty patients (9 males, 21 females; mean age, 51.5 years; range 23 to 73 years) with RA and 19 healthy individuals (7 males, 12 females; mean age 51 years; range 24 to 61 years) were included in this study.
💡
Conclusion & Impact:Widespread use of these parameters may be beneficial for the early diagnosis and effective treatment of RA and similar diseases resulting in bone deformities in the future.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: This study aims to evaluate the biomarkers of bone formation and resorption to determine the mechanism of bone deformities in patients with rheumatoid arthritis (RA). Patients and methods: Thirty patients (9 males, 21 females; mean age, 51.5 years; range 23 to 73 years) with RA and 19 healthy individuals (7 males, 12 females; mean age 51 years; range 24 to 61 years) were included in this study. Patients with RA were subgrouped according to disease activity (active, n=21, mean age 53.0; range 37 to 73 years; inactive, n=9, mean age 46.0; range 23 to 62 years). Levels of receptor activator of nuclear factor kappa B ligand (RANKL), osteoprotegerin (OPG), tartrate-resistant acid phosphatase-5b, tumor necrosis factor-alpha (TNF-&#945;), cathepsin-K, and activity of matrix metalloproteinase-3 (MMP-3) were measured in patient and control groups with enzyme-linked immunosorbent assay method. Results: Levels of RANKL, OPG, cathepsin-K, TNF-&#945; and MMP-3 activities of the patients were significantly higher when compared with the controls (p<0.05). A comparison of the active and inactive patients with RA revealed that OPG levels and MMP-3 activities were significantly higher in active group than inactives (p<0.05), while there was no significant difference in TNF-&#945;, RANKL levels, and tartrate-resistant acid phosphatase-5b and cathepsin-K activities between two groups (p>0.05). Conclusion: Increased RANKL, OPG, TNF-&#945;, cathepsin-K levels and MMP-3 activities in RA patients demonstrated that these parameters are related to bone deformities which occur in the process of RA. Widespread use of these parameters may be beneficial for the early diagnosis and effective treatment of RA and similar diseases resulting in bone deformities in the future.

Özet

Amaç:/b> Bu çalışmada romatoid artritli (RA) hastalarda kemik deformite mekanizmalarının belirlenmesi amacıyla kemik yapım ve yıkım belirteçleri değerlendirildi. Hastalar ve yöntemler: RA’lı 30 hasta (9 erkek, 21 kadın; ort. yaş 51.5 yıl; dağılım 23-73 yıl) ve 19 sağlıklı birey (7 erkek, 12 kadın; ort. yaş 51 yıl; dağılım 24-61 yıl) çalışmaya dahil edildi. RA’lı hastalar hastalık aktivitesine göre alt gruplara ayrıldı (aktif, n=21, ort. yaş 53.0; dağılım 37-73 yıl; inaktif, n=9, ort. yaş 46.0; dağılım 23-62 yıl). Hasta ve kontrol gruplarında reseptör aktivatör nükleer faktör kappa ligand (RANKL), osteoprotegerin (OPG), tartrat rezistan asit fosfataz-5b, tümör nekroz faktör alfa (TNF-α), katepsin K seviyeleri ve matriks metalloproteinaz-3 (MMP-3) aktivitesi enzime bağlı immünosorban yöntemi ile ölçüldü. Bulgular: Hastaların RANKL, OPG, katepsin-K, TNF-α seviyeleri ve MMP-3 aktiviteleri kontrollere kıyasla anlamlı olarak yüksekti (p 0.05), iki grup arasında TNF-α, RANKL seviyeleri ile tartrat rezistan asit fosfataz-5b ve katepsin-K aktiviteleri açısından anlamlı fark yoktu (p<0.05). Sonuç: RA’lı hastalarda artmış RANKL, OPG, TNF-α, katepsin-K seviyeleri ile MMP-3 aktiviteleri, bu parametrelerin RA sürecinde meydana gelen kemik deformiteleri ile ilişkili olduğunu gösterdi. Bu parametrelerin yaygın kullanımı, gelecekte RA’nın ve kemik deformiteleri ile sonuçlanan benzer hastalıkların erken tanı ve etkin tedavisinde yararlı olabilir.

🔖

Cite This Article

SUNAL, K. S., DOLBUN, K. S., ŞAHİN, A. S., CANİKLİOĞLU, A., BAŞKOL, G., DEMİR, H., ERSOY, E., DOÇER, D. (2015). Evaluation of various factors leading to osteolytic and antiosteolytic effects in patients with rheumatoid arthritis. art, Cilt: 30 - Sayı: 1, 45–50. https://ajindex.com/articles/199173

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Walsh NC, Crotti TN, Goldring SR, Gravallese EM. Rheumatic diseases: the effects of inflammation on bone. Immunol Rev 2005 Dec;208:228-51.
  2. Stewart A, Mackenzie LM, Black AJ, Reid DM. Predicting erosive disease in rheumatoid arthritis. A longitudinal study of changes in bone density using digital X-ray radiogrammetry: a pilot study. Rheumatology (Oxford) 2004;43:1561-4.
  3. Ritchlin CT, Schwarz EM, O’Keefe RJ, Looney RJ. RANK, RANKL and OPG in inflammatory arthritis and periprosthetic osteolysis. J Musculoskelet Neuronal Interact 2004;4:276-84.
  4. Jones DH, Kong YY, Penninger JM. Role of RANKL and RANK in bone loss and arthritis. Ann Rheum Dis 2002;61 Suppl 2:ii32-9. Pettit AR, Walsh NC, Manning C, Goldring SR, Gravallese EM. RANKL protein is expressed at the pannus-bone interface at sites of articular bone erosion in rheumatoid arthritis. Rheumatology (Oxford) 2006;45:1068-76.
  5. Wright HL, McCarthy HS, Middleton J, Marshall MJ. RANK, RANKL and osteoprotegerin in bone biology and disease. Curr Rev Musculoskelet Med 2009;2:56-64.
  6. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-76.
  7. Hofbauer LC, Heufelder AE. Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology. J Mol Med (Berl) 2001;79:243-53.
  8. Hou WS, Li Z, Gordon RE, Chan K, Klein MJ, Levy R, et al. Cathepsin k is a critical protease in synovial fibroblast-mediated collagen degradation. Am J Pathol 2001;159:2167-77.
  9. Goto T, Yamaza T, Tanaka T. Cathepsins in the osteoclast. J Electron Microsc (Tokyo) 2003;52:551-8.
  10. Chen CH, Lin KC, Yu DT, Yang C, Huang F, Chen HA, et al. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity. Rheumatology (Oxford) 2006;45:414-20.
  11. Zhu J, Yu DT. Matrix metalloproteinase expression in the spondyloarthropathies. Curr Opin Rheumatol 2006;18:364-8.
  12. Halleen JM, Alatalo SL, Janckila AJ, Woitge HW, Seibel MJ, Väänänen HK. Serum tartrate-resistant acid phosphatase 5b is a specific and sensitive marker of bone resorption. Clin Chem 2001;47:597-600.
  13. Halleen JM, Tiitinen SL, Ylipahkala H, Fagerlund KM, Väänänen HK. Tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of bone resorption. Clin Lab 2006;52:499-509.
  14. Schett G, Stolina M, Dwyer D, Zack D, Uderhardt S, Krönke G, et al. Tumor necro